Evidence map›Paper›PMID 31781782›Full record

ArticleDer Urologe. Ausg. A2020

[Changes in the treatment of metastatic prostate cancer-new data and open questions].

P Albers, M Bögemann, S Machtens, A S Merseburger, M Schostak, T Steuber, C Wülfing, M De Santis

Abstract read
PubMed Publisher
In one paragraph

Article in Der Urologe. Ausg. A, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

P AlbersKlinik für Urologie und Universitätstumorzentrum, Comprehensive Cancer Center, Universitätsklinikum, Medizinische Fakultät Heinrich-Heine-Universität, Düsseldorf, Moorenstraße 5, 40225, Düsseldorf, Deutschland. urologie@uni-duesseldorf.de.
M BögemannKlinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland.
S MachtensKlinik für Urologie und Kinderurologie, GFO Kliniken Rhein Berg, Betriebsstätte, Marien-Krankenhaus, Bergisch Gladbach, Deutschland.
A S MerseburgerKlinik für Urologie, Campus Lübeck, Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland.
M SchostakKlinik für Urologie und Kinderurologie, Universitätsklinik Magdeburg, Magdeburg, Deutschland.
T SteuberMartini-Klinik, Prostatakrebszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland.
C WülfingAbteilung für Urologie, Asklepios Klinik Altona, Hamburg, Deutschland.
M De SantisKlinik für Urologie, Interdisziplinäre Uro-Onkologie, Charité - Universitätsmedizin Berlin, Berlin, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The availability of taxane-based chemotherapy and androgen-receptor-targeted agents (ARTAs) have significantly broadened the therapeutic options for patients with metastatic prostate cancer and may also result in longer patient survival. The therapeutic sequence of ARTAs and taxanes may influence outcome and therefore decisions should be made on an individual basis. This article provides guidance for therapeutic decision-making in daily clinical practice by working out criteria that can be used to support individual therapeutic decisions. The focus is on metastatic castration-naive prostate cancer, oligometastatic disease as well as non-metastatic and metastatic castration-resistant prostate cancer.

Indexed as

Androgen AntagonistsAntineoplastic Agents, HormonalHormone Replacement TherapyHumansMaleMolecular Targeted TherapyProstatectomyProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantTreatment OutcomeAndrogen AntagonistsAntineoplastic Agents, HormonalProstate-Specific AntigenAndrogen receptorChemotherapyOligometastasesProstatic neoplasms, castration-naiveSystemic therapy

Identifiers

PMID31781782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.